AT2 receptors: Potential therapeutic targets for hypertension

American Journal of Hypertension

Volumn 30, Issue 4, 2017, Pages 339-347

  Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Angiotensin II infusion model; Angiotensin receptors; Antihypertensive agent; AT2 receptor activation; Blood pressure; Cell signaling; Experimental hypertension; Hypertension; Natriuresis; Receptor trafcking; Sodium excretion; Sodium transporters; Sodium hydrogen exchanger 3; Sodium potassium ATPase; Treatment of hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; SODIUM; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BRADYKININ; SODIUM PROTON EXCHANGE PROTEIN 3;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; HUMAN; HYPERTENSION; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; AGONISTS; ANIMAL; BLOOD PRESSURE; CELL MEMBRANE; CYTOLOGY; DISEASE MODEL; KIDNEY PROXIMAL TUBULE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; CELL MEMBRANE; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; NATRIURESIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SODIUM-HYDROGEN EXCHANGER 3; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 85020507936     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpw121     Document Type: Review

References (93)

1. Willey JZ, Moon YP, Kahn E, Rodriguez CJ, Rundek T, Cheung K, Sacco RL, Elkind MS. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc 2014; 3:e001106.
2. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, Balkrishnan R, Chen JL, Cope E, Eggers P W, Gillen D, Gipson D, Hailpern SM, Hall YN, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ, Kalantar-Zadeh K, Kovesdy C P, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, Nguyen DV, O'Hare AM, Plattner B, Pisoni R, Port FK, Rao P, Rhee CM, Sakhuja A, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, White S, Woodside K, Hirth RA. US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2016; 67(Suppl 1):Svii, S1-S305.
3. Guyton AC, Coleman TG, Young DB, Lohmeier TE, DeClue JW. Salt balance and long-term blood pressure control. Annu Rev Med 1980; 31:15-27.
4. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52:584-594.
5. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24:261-271.
6. Carey RM. Newly discovered components and actions of the renin-angiotensin system. Hypertension 2013; 62:818-822.
7. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013; 216:R1-R17.
8. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Kemplin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013; 112:1104-1111.
9. Carey RM. Te intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure. Hypertension 2013; 61:673-680.
10. Carey RM, Padia SH. AT2 receptors: benefcial counter-regulatory role in cardiovascular and renal function. Pfugers Arch 2013; 465:99-110.
11. Unger TM, Steckelings UM, Santos RAS. Te Protective Arm of the Renin Angiotensin System: Functional Aspects and Terapeutic Implications. Elsevier Academic Press: Amsterdam, 2015.
12. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Grifths R, Kumar A P, Kim HS, Smithies O, Le TH, Cofman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103:17985-17990.
13. Gurley SB, Riquier-Brison AD, Schnermann J, Sparks MA, Allen AM, Haase VH, Snouwaert JN, Le TH, McDonough AA, Koller BH, Cofman TM. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab 2011; 13:469-475.
14. Sumners C, de Kloet AD, Krause EG, Unger T, Steckelings UM. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol 2015; 21:115-121.
15. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003; 140:809-824.
16. Henrion D, Kubis N, Lévy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001; 38:1150-1157.
17. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ter 2008; 120:292-316.
18. Zwart AS, Davis EA, Widdop RE. Modulation of AT1 receptor-mediated contraction of rat uterine artery by AT2 receptors. Br J Pharmacol 1998; 125:1429-1436.
19. Hannan RE, Davis EA, Widdop RE. Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol 2003; 140:987-995.
20. de Gasparo M, Catt KJ, Inagami T, Wright J W, Unger T. International union of pharmacology. XXIII. Te angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
21. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular efects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377:744-747.
22. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Efects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 recep-t o r. Nature 1995; 377:748-750.
23. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96:6506-6510.
24. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935.
25. Carey RM, Howell NL, Jin X-H, Siragy HM. Angiotensin type-2 (AT2) receptor-mediated hypotension in type-1 (AT1) receptor-blocked rats. Hypertension 2001; 38:1272-1277.
26. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary bio-chemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163:284-291.
27. Wan Y, Wallinder C, Ploufe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the frst selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47:5995-6008.
28. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Tomas WG, Widdop RE. Relative afnity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011; 121:297-303.
29. Danyel LA, Schmerler P, Paulis L, Unger T, Steckelings UM. Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integr Blood Press Control 2013; 6:153-161.
30. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor efects in conscious sponta-neously hypertensive rats. Br J Pharmacol 2010; 159:709-716.
31. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE, Denton KM. Sex-specifc infuence of angiotensin type-2 receptor stimulation on renal function. Hypertension 2012; 59:409-414.
32. Del Borgo M, Wang Y, Bosnyak S, Khan M, Walters P, Spizzo I, Perlmutter P, Hilliard L, Denton K, Aguilar MI, Widdop RE, Jones ES. β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats. Clin Sci (Lond) 2015; 129:505-513.
33. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35:1074-1077.
34. Jones ES, Del Borgo MP, Kirsch JF, Clayton D, Bosnyak S, Welungoda I, Hausler N, Unabia S, Perlmutter P, Tomas WG, Aguilar MI, Widdop RE. A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function. Hypertension 2011; 57:570-576.
35. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003; 42:600-604.
36. Matsubara H, Shibasaki Y, Okigaki M, Mori Y, Masaki H, Kosaki A, Tsutsumi Y, Uchiyama Y, Fujiyama S, Nose A, Iba O, Tateishi E, Hasegawa T, Horiuchi M, Nahmias C, Iwasaka T. Efect of angioten-sin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Biochem Biophys Res Commun 2001; 282:1085-1091.
37. Andressen BT, Romero GC, Jackson EK. AT2 receptors attenuate AT1 receptor-induced phospholipase D activation in vascular smooth muscle cells. J Pharmacol Exp Ter 2004; 309:425-431.
38. Dao VT, Medini S, Bisha M, Balz V, Suvorava T, Bas M, Kojda G. Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors. Biochem Pharmacol 2016; 112:24-36.
39. Zhuo JAA, Alcorn D, Aldred GP, MacGregor DP, Mendelsohn FA. Te distribution of angiotensin II receptors. Hypertension 1995; 35:155-163.
40. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997; 30:1238-1246.
41. Miyata N, Park F, Cowley AW Jr. Distribution of AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol 1999; 277:F437-446.
42. Carey RM, Padia SH. Role of angiotensin AT(2) receptors in natriuresis: intrarenal mechanisms and therapeutic potential. Clin Exp Pharmacol Physiol 2013; 40:527-534.
43. Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 2006; 47:537-544.
44. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, Roques B P, Carey RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 2007; 49:625-630.
45. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP, Carey RM. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 2008; 51:460-465.
46. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, Padia SH, Carey RM. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 2012; 60:387-395.
47. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upreg-ulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 2005; 45:270-275.
48. Hakam AC, Siddiqui AH, Hussain T. Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats. Am J Physiol Renal Physiol 2006; 290:F503-F508.
49. Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na+-K+-ATPase activity via a NO/cGMP-dependent pathway. Am J Physiol Renal Physiol 2006; 290:F1430-F1436.
50. Hakam AC, Hussain T. Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats. Hypertension 2006; 47:1117-1124.
51. Ali Q, Hussain T. AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats. Hypertens Res 2012; 35:654-660.
52. Gross V, Schunck WH, Honeck H, Milia AF, Kärgel E, Walther T, Bader M, Inagami T, Schneider W, Luf FC. Inhibition of pressure natriuresis in mice lacking the AT2 receptor. Kidney Int 2000; 57:191-202.
53. Hilliard LM, Nematbakhsh M, Kett MM, Teichman E, Sampson AK, Widdop RE, Evans RG, Denton KM. Gender diferences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor. Hypertension 2011; 57:275-282.
54. Brown RD, Hilliard LM, Head GA, Jones ES, Widdop RE, Denton KM. Sex diferences in the pressor and tubuloglomerular feedback response to angiotensin II. Hypertension 2012; 59:129-135.
55. Mirabito KM, Hilliard LM, Kett MM, Brown RD, Booth SC, Widdop RE, Moritz KM, Evans RG, Denton KM. Sex-and age-related difer-ences in the chronic pressure-natriuresis relationship: role of the angio-tensin type 2 receptor. Am J Physiol Renal Physiol 2014; 307:F901-F907.
56. Jin XH, McGrath HE, Gildea JJ, Siragy HM, Felder RA, Carey RM. Renal interstitial guanosine cyclic 3 ', 5'-monophosphate mediates pressure-natriuresis via protein kinase G. Hypertension 2004; 43:1133-1139.
57. Ahmed F, Kemp BA, Howell NL, Siragy HM, Carey RM. Extracellular renal guanosine cyclic 3'5'-monophosphate modulates nitric oxide and pressure-induced natriuresis. Hypertension 2007; 50:958-963.
58. Lieb DC, Kemp BA, Howell NL, Gildea JJ, Carey RM. Reinforcing feedback loop of renal cyclic guanosine 3' 5'-monophosphate and interstitial hydrostatic pressure in pressure-natriuresis. Hypertension 2009; 54:1278-1283.
59. 2 receptor activation induces natriuresis and lowers blood pressure. Circ Res 2014; 115:388-399.
60. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33:1237-1242.
61. Kemp BA, Howell NL, Keller SR, Gildea JJ, Padia SH, Carey RM. AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension. Circ Res 2016; 119:532-543.
62. Wang T. Flow-activated transport events along the nephron. Curr Opin Nephrol Hypertens 2006; 15:530-536.
63. Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev 2011; 19:276-278.
64. Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 2007; 49:155-161.
65. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension 2012; 59:437-445.
66. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, Carey RM. Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension 2009; 53:338-343.
67. Padia SH, Howell NL, Kemp BA, Fournie-Zaluski MC, Roques B P, Carey RM. Intrarenal aminopeptidase N inhibition restores defective angiotensin II type 2-mediated natriuresis in spontaneously hypertensive rats. Hypertension 2010; 55:474-480.
68. Droney JR, Pfeger KD. G protein coupled receptors as drug targets: the role of beta-arrestins. Endocr Metab Immune Disord Drug Targets 2008; 8:51-61.
69. Hein L, Meinel L, Pratt RE, Dzau VJ, Kobilka BK. Intracellular trafck-ing of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997; 11:1266-1277.
70. Gwathmey TM, Shaltout HA, Pendergrass KD, Pirro NT, Figueroa J P, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol 2009; 296:F1484-F1493.
71. Porrello ER, Pfeger KD, Seeber RM, Qian H, Oro C, Abogadie F, Delbridge LM, Tomas WG. Heteromerization of angiotensin receptors changes trafcking and arrestin recruitment profles. Cell Signal 2011; 23:1767-1776.
72. Turu G, Szidonya L, Gáborik Z, Buday L, Spät A, Clark AJ, Hunyady L. Diferential beta-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett 2006; 580:41-45.
73. Miura S, Karnik SS, Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem 2005; 280:18237-18244.
74. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved afer long-term AT1 receptor blockade. Hypertension 2002; 40:516-520.
75. Rodrigues-Ferreira S, Nahmias C. An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab 2010; 21:684-690.
76. Nascimento NR, Kemp BA, Howell NL, Gildea JJ, Santos CF, Harris TE, Carey RM. Role of SRC family kinase in extracellular renal cyclic guanosine 3', 5'-monophosphate-and pressure-induced natriuresis. Hypertension 2011; 58:107-113.
77. Sabuhi R, Asghar M, Hussain T. Inhibition of NAD(P)H oxidase potentiates AT2 receptor agonist-induced natriuresis in Sprague-Dawley rats. Am J Physiol Renal Physiol 2010; 299:F815-F820.
78. Alexander LD, Ding Y, Alagarsamy S, Cui XL, Douglas JG. Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor. Kidney Int 2006; 69:1823-1832.
79. Duke LM, Evans RG, Widdop RE. AT2 receptors contribute to acute blood pressure-lowering and vasodilator efects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 288:H2289-H2297.
80. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker efects on kidney fbrosis. Am J Physiol Renal Physiol 2010; 298:F683-F691.
81. Savoia C, Touyz RM, Volpe M, Schifrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007; 49:341-346.
82. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol 2004; 142:821-830.
83. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schifrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fbrosis in stroke-prone spontaneously hyper-tensive rats. Hypertension 2012; 59:291-299.
84. Paulis L, Becker ST, Lucht K, Schwengel K, Slavic S, Kaschina E, Töne-Reineke C, Dahlöf B, Baulmann J, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the efect on pulse wave velocity and aortic remodeling. Hypertension 2012; 59:485-492.
85. Ali Q, Patel S, Hussain T. Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats. Am J Physiol Renal Physiol 2015; 308:F1379-F1385.
86. 2 receptor agonist, to the striatum in rats. J Neurosci Methods 2011;202:137-142.
87. Gross V, Milia AF, Plehm R, Inagami T, Luf FC. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens 2000; 18:955-961.
88. Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH. Efects of angiotensin type 2 receptor overexpression in the rostral ventrolat-eral medulla on blood pressure and urine excretion in normal rats. Hypertension 2008; 51:521-527.
89. Blanch GT, Freiria-Oliveira AH, Speretta GF, Carrera EJ, Li H, Speth RC, Colombari E, Sumners C, Colombari DS. Increased expression of angiotensin II type 2 receptors in the solitary-vagal complex blunts renovascular hypertension. Hypertension 2014; 64:777-783.
90. Gao J, Zhang H, Le KD, Chao J, Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens 2011; 24:724-730.
91. Gao L, Zucker IH. AT2 receptor signaling and sympathetic regulation. Curr Opin Pharmacol 2011; 11:124-130.
92. Gao J, Zucker IH, Gao L. Activation of central angiotensin type 2 receptors by compound 21 improves arterial barorefex sensitivity in rats with heart failure. Am J Hypertens 2014; 27:1248-1256.
93. Brouwers S, Smolders I, Wainford RD, Dupont AG. Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats. Clin Sci (Lond) 2015; 129:81-92.